Related Experiment Videos
[Cell transplantation therapy for Parkinson's disease]
Nihon Rinsho. Japanese Journal of Clinical Medicine
|November 9, 2000
Summary
Parkinson's disease patients showed reduced "off" time after receiving thoracic sympathetic ganglia grafts. This novel transplantation approach offers a promising new avenue for Parkinson's disease symptom management.
Area of Science:
- Neurosurgery
- Neurology
- Regenerative Medicine
Context:
- Parkinson's disease (PD) is a progressive neurodegenerative disorder.
- Current treatments for PD, including levodopa, manage symptoms but do not halt disease progression.
- Autotransplantation of sympathetic ganglia has shown potential in improving PD symptoms.
Purpose:
- To evaluate the efficacy of endoscopically harvested thoracic sympathetic ganglia grafts in Parkinson's disease patients.
- To assess the impact of CT-guided stereotaxic transplantation into the caudate head and putamen on motor and non-motor symptoms.
- To determine the long-term effects of this novel grafting procedure on medication requirements and quality of life.
Summary:
- Four Parkinson's disease patients received unilateral grafts of endoscopically harvested thoracic sympathetic ganglia, with deposits placed in the caudate head and putamen.
- Post-transplantation follow-up revealed a 30-40% reduction in "off" time (periods of symptom exacerbation) in all patients.
- Two patients experienced a reduction in dyskinesia during their "on" periods (when medication is effective).
Impact:
- This modified transplantation technique using thoracic sympathetic ganglia shows encouraging results for managing Parkinson's disease symptoms, particularly "off" time.
- The procedure may lead to a reduced need for antiparkinsonian medication and improved patient outcomes.
- Further investigation is warranted to validate this promising therapeutic paradigm for Parkinson's disease.